QPPV.COM KNOWLEDGE ASSESSMENT

Inotuzumab Ozogamicin: Classification, Mechanism, ALL Use and Pharmacovigilance

Test your understanding of the concepts covered by Inotuzumab Ozogamicin: Classification, Mechanism, ALL Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is CD22 a suitable target for inotuzumab ozogamicin?

CD22 is a B-lineage antigen capable of internalisation after antibody binding CD22 is expressed exclusively on hepatocytes and transports the payload into the liver CD22 prevents all immune-mediated adverse reactions to the conjugate CD22 directly repairs DNA damage caused by calicheamicin

Question 2 of 10 Which sequence most accurately represents the principal mechanism of action of inotuzumab ozogamicin?

CD22 binding, internalisation, intracellular payload release, DNA damage and apoptosis CD22 blockade, extracellular calicheamicin activation, renal excretion and apoptosis DNA binding, antibody synthesis, CD22 downregulation and immune tolerance Hepatic metabolism, direct platelet inhibition, DNA repair inhibition and cell-cycle arrest

Question 3 of 10 Which inspection evidence would best demonstrate that a PV system understands the principal risk pathway for inotuzumab ozogamicin?

Evidence that cases capture cumulative exposure, transplant timing, conditioning and liver-risk factors, with medical review for SOS/VOD Evidence that only infusion dates are retained Evidence that all hepatic cases are excluded after treatment discontinuation Evidence that cytopenia, infection and bleeding are always processed as unrelated events

Question 4 of 10 Which statement best explains why cytopenias in a patient receiving inotuzumab ozogamicin require contextual causality assessment?

They can result from the disease, prior therapy and the ADC, so baseline counts, treatment timing and recovery are needed They are necessarily caused by CD22 expression on platelets They can occur only after HSCT and not during ADC therapy They have no relevance to infection, bleeding or transfusion support

Question 5 of 10 Why does a subsequent allogeneic HSCT materially change pharmacovigilance assessment after inotuzumab ozogamicin exposure?

HSCT eliminates any possibility that an earlier medicine contributed to a later event Transplant conditioning and the post-transplant state can interact with prior hepatic vulnerability associated with ADC exposure HSCT converts the ADC into an unconjugated antibody with a different target Only adverse events occurring after engraftment are relevant to the medicine

Question 6 of 10 What is the most appropriate pharmacovigilance interpretation of toxicity associated with inotuzumab ozogamicin?

All important adverse reactions should be attributed solely to CD22 blockade Safety findings should be interpreted through the integrated antibody, linker, payload and treatment-sequence characteristics Only adverse reactions occurring during the infusion are plausibly related to the medicine The cytotoxic payload is relevant to efficacy but not to organ-specific safety

Question 7 of 10 Which overall safety model most accurately reflects the article's central pharmacovigilance message?

Drug exposure should be assessed only against events occurring before the final dose The relevant model links ADC exposure, hepatic vulnerability, transplantation and post-transplant outcomes while also integrating marrow toxicity and infection The antibody target alone is sufficient to predict and classify all adverse reactions Aggregate safety review should focus exclusively on laboratory abnormalities

Question 8 of 10 Why is recording only the term 'hepatotoxicity' insufficient in a serious case involving inotuzumab ozogamicin?

The term provides no information about whether the patient had ALL It may obscure a clinically coherent SOS/VOD syndrome and omit key features needed for diagnosis and risk assessment It proves that the event was caused by a concomitant medicine It prevents assessment of any non-hepatic adverse reaction

Question 9 of 10 A patient has severe thrombocytopenia during treatment and later develops gastrointestinal bleeding requiring transfusion. What is the strongest PV approach?

Record thrombocytopenia only because bleeding is a separate clinical issue Link the cytopenia, bleeding and transfusion at patient level when assessing seriousness and clinical impact Record only the transfusion because laboratory abnormalities are not clinically relevant Assume the bleeding cannot be related because ALL itself can cause cytopenia

Question 10 of 10 Which statement best describes the role of cumulative exposure in inotuzumab ozogamicin pharmacovigilance?

Cumulative exposure is irrelevant once the last dose has been administered Cumulative cycles can help characterise hepatic risk and should be retained in case assessment and aggregate analyses Only the first dose determines all later safety outcomes Cumulative exposure is relevant only to infusion reactions

Inotuzumab Ozogamicin: Classification, Mechanism, ALL Use and Pharmacovigilance

Cookie Settings